Ascendis Pharma A (ASND) Total Debt (2021 - 2026)

Ascendis Pharma A has reported Total Debt for 6 years, with the latest figure at $864.8 million in Q1 2026.

• Quarterly Total Debt fell 16.23% year-over-year to $864.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $864.8 million (down 16.23% YoY) and the FY2025 annual result came in at $1.2 billion, up 41.69% from the prior year.
• Total Debt declined to $864.8 million in Q1 2026 per ASND's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Total Debt peaked at $1.2 billion in Q4 2025 and troughed at $407.3 million in Q4 2022.
• A 5-year average of $793.2 million and a median of $864.8 million in 2026 frame the typical range for Total Debt.
• The sharpest annual moves came in 2022 and 2026: Total Debt jumped 239.19% in 2022, then declined 16.23% in 2026.
• Over 5 years, Total Debt stood at $407.3 million in 2022, then soared by 66.46% to $677.9 million in 2023, then gained by 29.77% to $879.8 million in 2024, then surged by 41.69% to $1.2 billion in 2025, then slumped by 30.63% to $864.8 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $864.8 million, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.